Company Description

Skeletalis is developing the next generation of therapies for musculoskeletal diseases. The company’s first small molecule candidate is a first-in-class, bone-targeted osteoporosis treatment designed to prevent fractures and preserve bone mineral density while avoiding the safety liabilities that have constrained existing therapies.